Leerink Partnrs Has Strong Estimate for AQST FY2024 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn ($0.47) per share for the year, up from their previous estimate of ($0.50). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Aquestive Therapeutics’ Q4 2024 earnings at ($0.14) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $12.69 million. During the same period last year, the company posted ($0.03) earnings per share.

Other research analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday. Leerink Partners boosted their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $8.83.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $5.08 on Friday. The stock has a 50-day simple moving average of $4.92 and a 200 day simple moving average of $3.84. Aquestive Therapeutics has a twelve month low of $1.55 and a twelve month high of $6.23.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics in the second quarter valued at about $27,000. nVerses Capital LLC bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at approximately $28,000. SG Americas Securities LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter worth approximately $54,000. The Manufacturers Life Insurance Company acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $76,000. Finally, Financial Advocates Investment Management lifted its position in shares of Aquestive Therapeutics by 70.0% during the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after buying an additional 14,000 shares during the period. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.